

REFERENCE

1. Benseler SM, Silverman ED. Systemic lupus erythematosus. *Pediatr Clin North Am.* 2005;52(2):443–467. doi:10.1016/j.pcl.2005.01.010.
2. Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. *Pediatr Clin North Am.* 2012;59(2):345–364. doi:10.1016/j.pcl.2012.03.007.
3. Mina R, Brunner HI. Pediatric lupus: Are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? *Rheum Dis Clin North Am.* 2010;36(1):53–80. doi:10.1016/j.rdc.2009.12.012.
4. Andrade RM, Alarcón GS, Fernández M, et al. Accelerated damage accrual among men with systemic lupus erythematosus: Results from a multiethnic US cohort. *Arthritis Rheum.* 2007;56(2):622–630. doi:10.1002/art.22391.
5. Ortona E, Pierdominici M, Maselli A, et al. Sex-based differences in autoimmune diseases. *Ann Ist Super Sanita.* 2016;52(2):205–212. doi:10.4415/ANN_16_02_12.
6. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis.* 2019;78(9):1151–1159. doi:10.1136/annrheumdis-2018-214819.
7. Bader-Meunier B, et al. Initial presentation of childhood-onset systemic lupus erythematosus: A French multicenter study. *J Pediatr.* 2005;146(5):648–653. doi:10.1016/j.jpeds.2004.12.045.
8. Isenberg DA, Rahman A, Allen E, et al. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index (BILAG-2004). *Rheumatology (Oxford).* 2005;44(7):902–906. doi:10.1093/rheumatology/keh624.
9. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res (Hoboken).* 2012;64(6):797–808. doi:10.1002/acr.21664.
10. Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An update on the management of childhood-onset systemic lupus erythematosus. *Paediatr Drugs.* 2021;23(4):331–347. doi:10.1007/s40272-021-00457-z.
11. Han J, Li X, Luo X, et al. Mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: Inhibition of dendritic cell functions via Toll-like receptor 9 signaling. *Biomed Pharmacother.* 2020;132:110848. doi:10.1016/j.biopha.2020.110848.
12. Yusuf IH, Issa PC, Ahn SJ. Hydroxychloroquine-induced retinal toxicity. *Front Pharmacol.* 2023;14:1196783. doi:10.3389/fphar.2023.1196783.
13. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. *Transplantation.* 2005;80(Suppl 2):S181–S190. doi:10.1097/01.tp.0000181108.77412.09.
14. Jiang YP, Zhao XX, Chen RR, et al. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus

- nephritis: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2020;99(38):e22328. doi:10.1097/MD.00000000000022328.
15. Kaur S, et al. Steroid-induced ocular hypertension in pediatric patients: incidence, risk factors, and management. *J Pediatr Ophthalmol Strabismus*. 2019;56(4):249–255. doi:10.3928/01913913-20190624-01.
 16. Feroze KB, Zeppieri M, Khazaeni L. Steroid-induced glaucoma [Internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 Jul 16 [cited 2025 Oct]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559169/>
 17. Nair PA, Saleh HM, Salazar FJ. Acneiform eruptions [Internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan 11 [cited 2025 Oct]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519550/>
 18. Fung MA, Berger TG. A prospective study of acute-onset steroid acne associated with administration of intravenous corticosteroids. *Dermatology*. 2000;200(1):43–44. doi:10.1159/000018314.
 19. Compston J. Management of glucocorticoid-induced osteoporosis. *Nat Rev Rheumatol*. 2010;6(2):82–88. doi:10.1038/nrrheum.2009.259.
 20. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. *Osteoporos Int*. 2007;18(10):1319–1328. doi:10.1007/s00198-007-0394-0.
 21. Putera AM, Irwanto I, Maramis MM, Prasetyo RV, Soemyarso NA, Noer MS. Effect of mental health problems on the quality of life in children with lupus nephritis. *Neuropsychiatr Dis Treat*. 2020;16:1583–1593. doi:10.2147/NDT.S250373.
 22. Blamires J, Foster M, Napier S, Dickinson A. Experiences and perspectives of children and young people living with childhood-onset systemic lupus erythematosus—An integrative review. *Children (Basel)*. 2023;10(6):1006. doi:10.3390/children10061006.
 23. Harper L, Ardoin SP, Leever A, Driest K, Sivaraman V, Taxter AJ. Automated mental health screening in pediatric lupus: Associations with disease features and treatment. *Front Pediatr*. 2024;12:1427543. doi:10.3389/fped.2024.1427543.
 24. Yoon S, Kang DH, Choi TY. Psychiatric symptoms in systemic lupus erythematosus: Diagnosis and treatment. *J Rheum Dis*. 2019;26(2):93–103. doi:10.4078/jrd.2019.26.2.93.
 25. Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY. Risk of herpes zoster in patients with systemic lupus erythematosus: A three-year follow-up study using a nationwide population-based cohort. *Clinics (Sao Paulo)*. 2011;66(7):1177–1182. doi:10.1590/S1807-59322011000700009.
 26. Navarra SV, Leynes MS. Infections in systemic lupus erythematosus. *Lupus*. 2010;19(12):1419–1424. doi:10.1177/0961203310374486.
 27. Fischer Kunzler AL, Tsokos GC. Infections in patients with systemic lupus erythematosus: The contribution of primary immune defects versus treatment-induced immunosuppression. *Eur J Rheumatol*. 2023;10(4):148–158. doi:10.5152/eurjrheum.2023.23068.
 28. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2024 update [Internet]. Available from: <https://ginasthma.org/2024-report/>

29. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2008;67(2):195–205. doi:10.1136/ard.2007.070367.
30. Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. *Cochrane Database Syst Rev*. 1998;(2):CD000952. doi:10.1002/14651858.CD000952.
31. Kokori SI, Ioannidis JPA, Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. *Am J Med*. 2000;108(3):198–204. doi:10.1016/S0002-9343(99)00413-1.
32. Gormezano NWS, Kern D, Pereira OL, et al. Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: Differences between pediatric and adult patients. *Lupus*. 2017;26(4):426–430. doi:10.1177/0961203316676379.
33. Piga M, Vacca A, Porru G, Cauli A, Mathieu A. Liver involvement in systemic lupus erythematosus: Incidence, clinical course and outcome of lupus hepatitis. *Clin Exp Rheumatol*. 2010;28(4):504–510. PMID:20609296.
34. Bader-Meunier B, Quartier P, Deschênes G, et al. [Childhood-onset systemic lupus erythematosus] [Article in French]. *Arch Pediatr*. 2003;10(2):147–157. doi:10.1016/S0929-693X(03)00313-0.
35. Lopes SRM, Gormezano NWS, Gomes RC, et al.; Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups. *Lupus*. 2017;26(9):996–1001. doi:10.1177/0961203317690616.